81 related articles for article (PubMed ID: 16515579)
21. Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer.
Einenkel J; Ott R; Handzel R; Braumann UD; Horn LC
Int J Gynecol Cancer; 2009 Oct; 19(7):1288-97. PubMed ID: 19823067
[TBL] [Abstract][Full Text] [Related]
22. Serous surface papillary carcinoma. A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma.
Mills SE; Andersen WA; Fechner RE; Austin MB
Am J Surg Pathol; 1988 Nov; 12(11):827-34. PubMed ID: 3189692
[TBL] [Abstract][Full Text] [Related]
23. Clinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (OMMMT) from a tertiary cancer institute: A series of 27 cases.
Menon S; Deodhar K; Rekhi B; Dhake R; Gupta S; Ghosh J; Maheshwari A; Mahantshetty U; Shrivastva S; Budukh A; Tongaonkar HB; Kerkar R
Indian J Pathol Microbiol; 2013; 56(4):365-71. PubMed ID: 24441223
[TBL] [Abstract][Full Text] [Related]
24. Hematogenous Splenic Metastases as an Independent Negative Prognosis Factor at the Moment of Primary Cytoreduction in Advanced Stage Epithelial Ovarian Cancer--A Single Center Experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Oct; 35(10):5649-54. PubMed ID: 26408738
[TBL] [Abstract][Full Text] [Related]
25. Malignant mixed Mullerian tumours of the uterus--a ten-year experience.
Ho SP; Ho TH
Singapore Med J; 2002 Sep; 43(9):452-6. PubMed ID: 12568422
[TBL] [Abstract][Full Text] [Related]
26. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma].
Gao YN; Liu JX; Wang W; Li WF; Tang WS
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):171-3. PubMed ID: 15946570
[TBL] [Abstract][Full Text] [Related]
28. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
29. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences.
Soslow RA; Slomovitz BM; Saqi A; Baergen RN; Caputo TA
Gynecol Oncol; 2000 Dec; 79(3):430-7. PubMed ID: 11104615
[TBL] [Abstract][Full Text] [Related]
30. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis.
Jordan SJ; Green AC; Whiteman DC; Moore SP; Bain CJ; Gertig DM; Webb PM; ;
Int J Cancer; 2008 Apr; 122(7):1598-603. PubMed ID: 18058817
[TBL] [Abstract][Full Text] [Related]
31. Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.
Gasimli K; Braicu EI; Richter R; Chekerov R; Sehouli J
Ann Surg Oncol; 2015 Aug; 22(8):2729-37. PubMed ID: 25672560
[TBL] [Abstract][Full Text] [Related]
32. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
34. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis.
Rauh-Hain JA; Diver EJ; Clemmer JT; Bradford LS; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
Gynecol Oncol; 2013 Oct; 131(1):46-51. PubMed ID: 23906658
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of peritoneal cancer index in primary advanced ovarian cancer.
Llueca A; Escrig J;
Eur J Surg Oncol; 2018 Jan; 44(1):163-169. PubMed ID: 29198495
[TBL] [Abstract][Full Text] [Related]
36. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
37. Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey.
Fagö-Olsen CL; Høgdall C; Kehlet H; Christensen IJ; Ottesen B
Acta Obstet Gynecol Scand; 2011 Mar; 90(3):273-9. PubMed ID: 21306310
[TBL] [Abstract][Full Text] [Related]
38. Total colectomy as part of primary cytoreductive surgery in advanced Müllerian cancer.
Song YJ; Lim MC; Kang S; Seo SS; Park JW; Choi HS; Park SY
Gynecol Oncol; 2009 Aug; 114(2):183-7. PubMed ID: 19427682
[TBL] [Abstract][Full Text] [Related]
39. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Casey MJ; Bewtra C
Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
[TBL] [Abstract][Full Text] [Related]
40. [Clinicopathological analysis and differential diagnosis of primary peritoneal adenocarcinoma].
Gong HL; Wang CB; Zhang GJ; Li CF; Yang XY; Hou HL; Zhang XB
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):463-5. PubMed ID: 19567094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
